MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

74.82 -0.4

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

73.35

Max

74.84

Galvenie mērījumi
By Trading Economics
Ienākumi	-100M -229M
Pārdošana	46M 203M
Peļņas marža	-112.808
Darbinieki	1,402
EBITDA	4.7B 4.6B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+29.36% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.7B 12B
Iepriekšējā atvēršanas cena	75.22
Iepriekšējā slēgšanas cena	74.82

Ziņu noskaņojums

By Acuity

50%

166 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. apr. 17:11 UTC

Galvenie tirgus virzītāji

Galvenie ziņu notikumi

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2026. g. 2. apr. 17:10 UTC

Galvenie ziņu notikumi

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

2026. g. 3. apr. 00:00 UTC

Galvenie ziņu notikumi

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2026. g. 2. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2026. g. 2. apr. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2026. g. 2. apr. 21:01 UTC

Galvenie ziņu notikumi

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2026. g. 2. apr. 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Starbucks and Boyu Capital Finalize China JV

2026. g. 2. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 2. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 2. apr. 20:41 UTC

Peļņas

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026. g. 2. apr. 20:32 UTC

Tirgus saruna

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2026. g. 2. apr. 20:30 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026. g. 2. apr. 20:09 UTC

Tirgus saruna

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2026. g. 2. apr. 20:01 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026. g. 2. apr. 19:46 UTC

Tirgus saruna

Is Oil the New GameStop? -- Market Talk

2026. g. 2. apr. 19:35 UTC

Tirgus saruna

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2026. g. 2. apr. 19:29 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026. g. 2. apr. 19:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2026. g. 2. apr. 19:20 UTC

Tirgus saruna

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2026. g. 2. apr. 19:01 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2026. g. 2. apr. 19:00 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: Agreement Reached With American Train Dispatchers Association

2026. g. 2. apr. 18:24 UTC

Iegādes, apvienošanās, pārņemšana

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2026. g. 2. apr. 17:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2026. g. 2. apr. 17:32 UTC

Galvenie ziņu notikumi

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2026. g. 2. apr. 17:26 UTC

Peļņas

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026. g. 2. apr. 17:17 UTC

Tirgus saruna

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2026. g. 2. apr. 17:09 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

29.36% augšup

Prognoze 12 mēnešiem

Vidējais 97.19 USD 29.36%

Augstākais 120 USD

Zemākais 72 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

166 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.